A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
In this phase II multicenter study, the investigators aim to evaluate the efficacy and
tolerability of a novel taxane-cabazitaxel as single agent second-line chemotherapy for
metastatic urothelial carcinoma.